We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Aetna's New Generative AI Assistant Aims to Simplify Health Care
Read MoreHide Full Article
Key Takeaways
CVS Aetna is rolling out a generative AI assistant to streamline benefits navigation for members.
CVS Aetna's tool embeds AI across digital channels to deliver fast, personalized and easy-to-digest answers.
CVS Aetna's beta launch expands through 2026, adding proactive insights and multimodal interaction support.
CVS Health (CVS - Free Report) Aetna’s latest offering aligns with its strategic efforts to move away from the transactional approach to health care to a consumer health experience. The company is rolling out a generative AI-powered conversational experience in its digital channels that will simplify health care, allowing members to quickly and easily navigate their benefits for a personalized experience. Unlike other industry alternatives, where conversational AI is relegated to a chat window, Aetna is embedding generative AI across its end-to-end digital experience.
The embedded approach ensures the Aetna assistant synthesizes all relevant information for the member. It will deliver immediate, easy-to-digest answers for the user, removing the need to weed through links or complex content. According to the company, members will not need to use technical healthcare terminology such as “prior authorization" or “claims" to get answers, but instead can use plain language and receive a response that is personalized, easy to understand and visually dynamic.
Aetna initially launched the new capability to a beta population in October and will expand access throughout the year and in the first half of 2026. Near-term enhancements will include proactive AI insights for member and multimodal interaction support, including voice, text and screen-reader capability.
The assistant will also be embedded within Aetna Care Paths, a new digital offering available through the Aetna Health app, announced as part of the company’s ongoing technology investment to improve the experience for medical professionals and their patients. Featuring a U.S. patent-pending technology, Aetna Care Paths gives clarity about procedures and benefits that may be encountered and personalized care recommendations, all in one convenient location.
News From CVS Health Rivals — CAH & CNC
Cardinal Health (CAH - Free Report) recently completed the acquisition of Solaris Health, a leading urology management services organization (“MSO”). The buyout adds more than 750 providers across more than 250 practice locations in 14 states and adds immediate scale to the Urology Alliance within Cardinal Health's leading multi-specialty MSO platform, The Specialty Alliance. Further, the company delivered a 22% year-over-year revenue growth in the first quarter of fiscal 2026, while non-GAAP diluted earnings per share (EPS) increased 36%.
Centene Corp. (CNC - Free Report) company, Wellcare announced plans to offer Medicare Advantage (“MA”) to over 51 million beneficiaries in 32 states and Prescription Drug Plan (“PDP”) products to more than 8 million members across all 50 states. This includes 51 new counties across eight markets, with a focus on D-SNPs, enhancements to the Wellcare Spendables card and improving member experience.
CVS Stock Performance, Valuation and Estimates
Year to date, CVS Health’s shares have increased 70.5% compared with the industry’s 4.9% growth.
Image Source: Zacks Investment Research
CVS Health is trading at a forward 12-month price/sales (P/S) ratio of 0.24, lower than the industry average of 0.45.
Image Source: Zacks Investment Research
See how the analysts are projecting CVS Health’s 2025 and 2026 earnings.
Image: Bigstock
CVS Aetna's New Generative AI Assistant Aims to Simplify Health Care
Key Takeaways
CVS Health (CVS - Free Report) Aetna’s latest offering aligns with its strategic efforts to move away from the transactional approach to health care to a consumer health experience. The company is rolling out a generative AI-powered conversational experience in its digital channels that will simplify health care, allowing members to quickly and easily navigate their benefits for a personalized experience. Unlike other industry alternatives, where conversational AI is relegated to a chat window, Aetna is embedding generative AI across its end-to-end digital experience.
The embedded approach ensures the Aetna assistant synthesizes all relevant information for the member. It will deliver immediate, easy-to-digest answers for the user, removing the need to weed through links or complex content. According to the company, members will not need to use technical healthcare terminology such as “prior authorization" or “claims" to get answers, but instead can use plain language and receive a response that is personalized, easy to understand and visually dynamic.
Aetna initially launched the new capability to a beta population in October and will expand access throughout the year and in the first half of 2026. Near-term enhancements will include proactive AI insights for member and multimodal interaction support, including voice, text and screen-reader capability.
The assistant will also be embedded within Aetna Care Paths, a new digital offering available through the Aetna Health app, announced as part of the company’s ongoing technology investment to improve the experience for medical professionals and their patients. Featuring a U.S. patent-pending technology, Aetna Care Paths gives clarity about procedures and benefits that may be encountered and personalized care recommendations, all in one convenient location.
News From CVS Health Rivals — CAH & CNC
Cardinal Health (CAH - Free Report) recently completed the acquisition of Solaris Health, a leading urology management services organization (“MSO”). The buyout adds more than 750 providers across more than 250 practice locations in 14 states and adds immediate scale to the Urology Alliance within Cardinal Health's leading multi-specialty MSO platform, The Specialty Alliance. Further, the company delivered a 22% year-over-year revenue growth in the first quarter of fiscal 2026, while non-GAAP diluted earnings per share (EPS) increased 36%.
Centene Corp. (CNC - Free Report) company, Wellcare announced plans to offer Medicare Advantage (“MA”) to over 51 million beneficiaries in 32 states and Prescription Drug Plan (“PDP”) products to more than 8 million members across all 50 states. This includes 51 new counties across eight markets, with a focus on D-SNPs, enhancements to the Wellcare Spendables card and improving member experience.
CVS Stock Performance, Valuation and Estimates
Year to date, CVS Health’s shares have increased 70.5% compared with the industry’s 4.9% growth.
Image Source: Zacks Investment Research
CVS Health is trading at a forward 12-month price/sales (P/S) ratio of 0.24, lower than the industry average of 0.45.
Image Source: Zacks Investment Research
See how the analysts are projecting CVS Health’s 2025 and 2026 earnings.
Image Source: Zacks Investment Research
CVS currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.